Method for treating autism

Details Method for treating autism Method for treating autism

2004-12-21

2008-11-25

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S659000, C514S661000, C514S289000, C514S250000

Reexamination Certificate

active

07456224

ABSTRACT:
A method for treating autism comprising the step of administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 4122193 (1978-10-01), Scherm et al.
patent: 4273774 (1981-06-01), Scherm
patent: 4994467 (1991-02-01), Zimmerman
patent: 5061703 (1991-10-01), Bormann et al.
patent: 6057373 (2000-05-01), Fogel
patent: 6362226 (2002-03-01), Phillips et al.
patent: 2001/0044446 (2001-11-01), Phillips et al.
patent: 2006/0167032 (2006-07-01), Galer et al.
patent: WO 99/36064 (1999-07-01), None
patent: WO 03/061656 (2003-07-01), None
patent: WO 03/061656 (2003-07-01), None
patent: WO 2004/009062 (2004-01-01), None
patent: WO 2004/009062 (2004-01-01), None
patent: WO 2005/084655 (2005-09-01), None
patent: WO 2006/034187 (2006-03-01), None
patent: WO 2006/034465 (2006-03-01), None
Autistic Spectrum Disorders, Fact Sheet.
Chez, Michael G. et al.: “Neurologic treatment strategies in autism: An overview of medical intervention strategies”; Seminars in Pediatric Neurology, Saunders, Philadelphia, PA; vol. 11, No. 3, Sep. 2004 pp. 229-235, XP004666246, ISSN: 1071-9091.
Michael G. Chez et al., “Donepezil Hydrochloride: A Double-Blind Study in Autistic Children,” Journal of Pediatric Neurology 2003; 1(2): 83-88.
Michael G. Chez et al., “Memantine as Add-On Therapy in Pediatric Epileptic Patients: Effects on Cognitive Developmental and Seizure Frequency,” Abstract—American Epilepsy Society Abstract, Epilepsia 45 Suppl. 7:152 (Abst. 1.4.06), 2004.
Michael G. Chez et al., “Memantine Experience in Children and Adolescents with Autistic Spectrum Disorders,” Abstract—Annals of Neurology, vol. 56, Supp. 8, S109, Sep. 2004.
Michael G. Chez et al., “Neurologic Treatment strategies in Autism: An Overview of Medical Intervention Strategies,” Seminars in Pediatric Neurology, 229-235, 2004.
Bryan H. King et al., Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of children with Autistic Disorder, J. Am. Acad. Child Adolesc. Psychiatry, 40:6 Jun. 2001.
C.G. Parsons et al., Memantine is a Clinically Well ToleratedN-Methyl-D-Aspartate (NMDA) Receptor Antagonist—a Review of Preclinical Data, Neuropharmacology 38 (1999) 735-767.
David J. Posey, M.D. et al., A Pilot Study of D-Cycloserine in Subjects with Autistic Disorder, Am J Psychiatry 2004; 161:2115-2117).
A.E. Purcell, et al. “Postmortem Brain Abnormalities of the Glutamate Neurotransmitter System in Autism,” Neurology 2001; 57:1618-1628.
I.M. Sukhanov et al., “Effects of NMDA Receptor Channel Blockers, MK-801 and Memantine, on Locomotor Activity and Tolerance to Delay of Reward in Wistar-Kyoto and Spontaneously Hypertensive Rats,” Behavioral Pharmacology, vol. 15, No. 4, 263-271, 2004.

Affiliated with

Also associated with

Rating

Method for treating autism does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for treating autism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating autism will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4031194